FibroGen (FGEN) Scheduled to Post Quarterly Earnings on Monday

FibroGen (NASDAQ:FGEN) will be posting its quarterly earnings results after the market closes on Monday, May 6th. Analysts expect FibroGen to post earnings of ($0.31) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.15). The firm had revenue of $27.14 million for the quarter, compared to analysts’ expectations of $40.00 million. On average, analysts expect FibroGen to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

FibroGen Stock Performance

Shares of NASDAQ FGEN opened at $1.14 on Friday. FibroGen has a fifty-two week low of $0.33 and a fifty-two week high of $19.47. The stock has a market cap of $113.40 million, a price-to-earnings ratio of -0.39 and a beta of 0.88. The firm’s 50-day simple moving average is $1.73 and its 200 day simple moving average is $1.22.

Wall Street Analyst Weigh In

Separately, William Blair reaffirmed a “market perform” rating on shares of FibroGen in a research report on Tuesday, February 27th. One analyst has rated the stock with a sell rating and four have given a hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $17.00.

Insider Transactions at FibroGen

In other FibroGen news, CEO Thane Wettig acquired 50,000 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The stock was bought at an average cost of $1.91 per share, with a total value of $95,500.00. Following the acquisition, the chief executive officer now owns 470,178 shares in the company, valued at $898,039.98. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 2.39% of the stock is currently owned by company insiders.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.